Novan announces changes to management team

Novan has announced changes to its executive management team, including the appointment of Paula Brown Stafford to the newly created position of chief development officer.

Stafford has more than 30 years of experience in the biopharmaceutical services industry, most recently as president of clinical development at Quintiles. She will work with Joyce Rico, MD, MBA, chief medical officer, as Novan prepares for upcoming interactions with the FDA regarding a potential new drug application of SB204, a topical nitric oxide-releasing gel, according to a news release from the company.

“Paula brings a wealth of global development experience to Novan and will be a great resource as we advance product candidates through clinical testing,” Nathan Stasko, PhD, president and CEO of Novan, stated in the release. “Importantly, this addition will allow Dr. Rico to focus on expanding our pipeline into inflammatory skin diseases, utilizing her background in immunology and her specific experience with tacrolimus as a treatment for atopic dermatitis.”

Stanley Hollenbach, who had served as vice president of research and nonclinical development since joining Novan in March 2014, was promoted to senior vice president of research and development, according to the release.

The company also announced that Novan’s board of directors has appointed William L. Hodges as interim chief financial officer following the departure of Richard Peterson as chief financial officer. Hodges most recently served as chief financial officer and senior vice president of finance and administration of POZEN Inc.

Reference: www.novan.com